SE511373C2 - Preparation for the treatment of aphte - Google Patents
Preparation for the treatment of aphteInfo
- Publication number
- SE511373C2 SE511373C2 SE9704789A SE9704789A SE511373C2 SE 511373 C2 SE511373 C2 SE 511373C2 SE 9704789 A SE9704789 A SE 9704789A SE 9704789 A SE9704789 A SE 9704789A SE 511373 C2 SE511373 C2 SE 511373C2
- Authority
- SE
- Sweden
- Prior art keywords
- weight
- preparation
- formulation
- treatment
- xylitol
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 15
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000811 xylitol Substances 0.000 claims abstract description 15
- 235000010447 xylitol Nutrition 0.000 claims abstract description 15
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 15
- 229960002675 xylitol Drugs 0.000 claims abstract description 15
- 239000004378 Glycyrrhizin Substances 0.000 claims abstract description 9
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 9
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 9
- 229940047648 cocoamphodiacetate Drugs 0.000 claims abstract description 6
- 239000006072 paste Substances 0.000 claims abstract description 4
- 239000002775 capsule Substances 0.000 claims abstract description 3
- 229940112822 chewing gum Drugs 0.000 claims abstract description 3
- 235000015218 chewing gum Nutrition 0.000 claims abstract description 3
- 239000002324 mouth wash Substances 0.000 claims abstract description 3
- 229940051866 mouthwash Drugs 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 11
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 10
- 208000002399 aphthous stomatitis Diseases 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- -1 polyethylene Polymers 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000011775 sodium fluoride Substances 0.000 claims description 5
- 235000013024 sodium fluoride Nutrition 0.000 claims description 5
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000005498 polishing Methods 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 239000001587 sorbitan monostearate Substances 0.000 claims description 3
- 235000011076 sorbitan monostearate Nutrition 0.000 claims description 3
- 229940035048 sorbitan monostearate Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 abstract 1
- 239000000606 toothpaste Substances 0.000 description 7
- 229940034610 toothpaste Drugs 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 235000019502 Orange oil Nutrition 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
511573 10 15 20 25 30 35 2 fattar följande substanser, som aktiva ämnen: a) 5,0-10,0 vikt-% apelsinterpen, b) 0,1-3,0 vikt-% glycyrrhizin, c) 0,1-1,5 vikt-% xylitol, d) 1,0-10,0 vikt-% kokoamfodiacetat. 511573 10 15 20 25 30 35 2 comprises the following substances, as active substances: a) 5.0-10.0% by weight of orange interpen, b) 0.1-3.0% by weight of glycyrrhizin, c) 0.1- 1.5% by weight of xylitol, d) 1.0-10.0% by weight of cocoamphodiacetate.
Beredningen används för behandling av aphte.The preparation is used for the treatment of aphte.
Beredningen enligt föreliggande uppfinning kan administreras i form av munvatten, pasta, tabletter, kapslar eller tuggummi.The formulation of the present invention may be administered in the form of mouthwash, paste, tablets, capsules or chewing gum.
I en ytterliggare utföringsform av uppfinningen innefattar beredningen för behandling av aphte följande substanser förutom vatten: a) 5,0-10,0 vikt-% apelsinterpen, b) 0,1-3,0 vikt-% glycyrrhizin, c) 0,1-1,5 vikt-% xylitol, d) 1,0-10,0 vikt-% kokoamfodiacetat, e) 1,0-10,0 vikt-% polyetylen (20) sorbitan mono- stearat, f) 1,5-3,2 vikt-% karboximetylcellulosa, g) 0,2-0,5 vikt-% parahydroxibensoesyra metylester, h) 0,05-2,0 vikt-% natriumfluorid.In a further embodiment of the invention, the preparation for the treatment of aphthae comprises the following substances in addition to water: a) 5.0-10.0 wt.% Orange interpen, b) 0.1-3.0 wt.% Glycyrrhizin, c) 0.1 -1.5 wt% xylitol, d) 1.0-10.0 wt% cocoamphodiacetate, e) 1.0-10.0 wt% polyethylene (20) sorbitan monostearate, f) 1.5- 3.2% by weight of carboxymethylcellulose, g) 0.2-0.5% by weight of parahydroxybenzoic acid methyl ester, h) 0.05-2.0% by weight of sodium fluoride.
Beredningen innehåller även 1,0-5,0 vikt-% kiseldioxid, som polermedel.The preparation also contains 1.0-5.0% by weight of silica, as a polishing agent.
Beredningen enligt uppfinningen används för framställning av läkemedel för behandling av aphte.The preparation according to the invention is used for the preparation of medicaments for the treatment of aphthae.
Andra utföringsfomer av uppfinningen definieras av de underordnade kraven.Other embodiments of the invention are defined by the dependent claims.
Detalierad beskrivning av uppfinninqen.Detailed description of the invention.
Föreliggande uppfinning avser en beredning för behandling av olika former av aphte. Beredningen enligt föreliggande uppfinning innefattar apelsinterpener, vilka bl.a. ingår i apelsinolja. Apelsinterpenerna har visat sig vara synnerligen effektiva att fånga upp proteiner och polysackarider, och föra dessa bort fràn stället för angreppet. I den mest föredragna utföringsformen av före- 10 15 20 25 30 35 s11 373% 3 liggande beredning, ingår apelsinolja i beredningen.The present invention relates to a preparation for the treatment of various forms of aphthae. The preparation according to the present invention comprises orange interpenes, which i.a. included in orange oil. The orange interpenes have been shown to be extremely effective in capturing proteins and polysaccharides, and removing them from the site of attack. In the most preferred embodiment of the present 373% 3 formulation, orange oil is included in the formulation.
Apelsinolja är fettlösande och kan bl.a. lösa upp lipider i plack samt kan absorbera dessa.Orange oil is fat-dissolving and can i.a. dissolve lipids in plaques and can absorb them.
Kokoamfodiacetat är en amfotär tensid, som luck- rar upp placksiktet, därför möjliggör denna substans apelsinterpenernas goda effekt. Föreliggande beredning innefattar därför även kokoamfodiacetat. Tandkrämsformen innehåller ej natriumlaurylsulfat, som är en tensid. I en norsk vetenskaplig undersökning har G. Embery and G.Cocoa amphodiacetate is an amphoteric surfactant, which loosens the plaque screen, therefore this substance enables the good effect of orange interpenets. The present formulation therefore also includes cocoamphodiacetate. The toothpaste form does not contain sodium lauryl sulphate, which is a surfactant. In a Norwegian scientific study, G. Embery and G.
Rölla, Clinical and Biological Aspects of Dentifrices, sidorna 173-180, visat att natriumlaurylsulfat bidrar till aphte. I nämnda undersökning fann man att aphte slutade uppträda i ca. 70% av fallen, när natriumlauryl- sulfat uteslöts från tandkräm. De flesta av tandkrämerna, som finns på marknaden i dag innehåller natriumlauryl- sulfat.Rölla, Clinical and Biological Aspects of Dentifrices, pages 173-180, showed that sodium lauryl sulfate contributes to aphthae. In the said study it was found that aphte stopped appearing for approx. 70% of cases, when sodium lauryl sulphate was excluded from toothpaste. Most of the toothpastes on the market today contain sodium lauryl sulfate.
En annan substans, som gör föreliggande bered- ning gynnsam för behandling av aphte, är glycyrrhizin, som bl.a. ingår i extrakt från lakritsrot. Glycyrrhizin har bakterihämmande effekt och hämmar företrädesvis till- växt av streptococcus mutans. Glycyrrhizin är även pH- sänkande in vivo.Another substance which makes the present preparation favorable for the treatment of aphthae is glycyrrhizin, which i.a. included in extracts from licorice root. Glycyrrhizin has an antibacterial effect and preferably inhibits the growth of streptococcus mutans. Glycyrrhizin is also pH lowering in vivo.
En ytterligare substans, som ingår i föreliggan- de beredning, är xylitol. Xylitol verkar synergetiskt med ovan nämnda substanser och ökar således beredningens goda verkan. Bakterier tar upp xylitol, främst då andra sock- erarter är närvarande i ringa mängder. Xylitol verkar genom att hindra bakteriernas normala metabolism genom att bilda xylitolfosfat, som är giftigt för bakterierna och därför hindrar deras tillväxt. Bakterierna transpor- terar xylitolfosfat ut genom bakteriemembranen. Processen är mycket energikrävande, varför xylitolfosfatet ackumu- leras i bakterierna. En ytterligare fördel, som xylitol har, är att den inte bryts ner till organiska syror, som andra sockerarter gör. Med xylitol, som sötningsmedel, kan pH hållas på en mer gynnsam nivå och demineralisering av tandemaljen kan undvikas. 511 373 lO 15 20 25 30 35 4 För att undersöka verkan av kompositionen enligt uppfinningen gjordes en beredning i form av en tandkräm, där kompositionen innefattas. Beredningsformen i följande exempel begränsar således ej uppfinningen, men är till för att visa den form som administerades till de personer som ingick i studien.An additional substance included in the present formulation is xylitol. Xylitol acts synergistically with the above-mentioned substances and thus increases the good effect of the preparation. Bacteria take up xylitol, mainly when other sugars are present in small amounts. Xylitol works by inhibiting the bacteria's normal metabolism by forming xylitol phosphate, which is toxic to the bacteria and therefore prevents their growth. The bacteria transport xylitol phosphate out through the bacterial membranes. The process is very energy intensive, which is why the xylitol phosphate accumulates in the bacteria. An additional advantage that xylitol has is that it does not break down into organic acids, as other sugars do. With xylitol, as a sweetener, the pH can be kept at a more favorable level and demineralization of the tooth enamel can be avoided. 511 373 10 15 20 25 30 35 4 To investigate the effect of the composition according to the invention, a preparation in the form of a toothpaste was made, in which the composition is included. The dosage form in the following examples thus does not limit the invention, but is intended to show the form which was administered to the persons included in the study.
Beredning En tankräm iordningställdes genom att 10,0 g/kg glycyrrhizin och 22,0 g/kg karboximetylcellulosa torrbla- O ndades, varefter 100,0 g/kg glycerin 85 s-ig tillsattes under jämn omrörning tills blandningen var klumpfri. 50,0 g/kg Apelsinterpen, 50,0 g/kg polyetylen (20) sorbitan monostearat och 3,0 g/kg parahydroxibensoesyra metylester värmdes till 40'C under omrörning tills all parahydroxi- bensoesyra metylester var löst, varefter lösningen fick svalna till rumstemperatur. Den rumstempererade lösningen tillsattes blandningen under jämn omrörning. 10,0 g/kg Xylitoltol och 2,4 g/kg natriumfluorid löstes i 545,0 g/1 PQO och tillsattes blandningen. Tillsist löstes 50,0 g/kg kokoamfodiacetat i 127,6 g/l vatten och rördes ned i blandningen tillsammans med 30,0 g/kg kiseldioxid. Bland- ningen rödes därefter till en jämn pasta.Preparation A tank cream was prepared by dry mixing 10.0 g / kg glycyrrhizin and 22.0 g / kg carboxymethylcellulose, after which 100.0 g / kg glycerin 85 sg was added with steady stirring until the mixture was lump-free. 50.0 g / kg Orange interpen, 50.0 g / kg polyethylene (20) sorbitan monostearate and 3.0 g / kg parahydroxybenzoic acid methyl ester were heated to 40 ° C with stirring until all parahydroxybenzoic acid methyl ester was dissolved, after which the solution was allowed to cool to room temperature. The room temperature solution was added to the mixture with gentle stirring. 10.0 g / kg Xylitol tol and 2.4 g / kg sodium fluoride were dissolved in 545.0 g / l PQO and added to the mixture. Finally, 50.0 g / kg of cocoa amphodiacetate was dissolved in 127.6 g / l of water and stirred into the mixture together with 30.0 g / kg of silica. The mixture was then stirred into a smooth paste.
Pilotstudie För att undersöka effekten av beredningen, en- ligt föreliggande uppfinning, valdes 30 stycken personer med aftös stomatit i den orala slemmhinnan. Personerna i studien behandlades med tandkrämen utan extra vatten vid varje applikationsstillfälle dagligen under sex månader.Pilot study To investigate the effect of the preparation, according to the present invention, 30 people with aphthous stomatitis in the oral mucosa were selected. The subjects in the study were treated with the toothpaste without extra water at each application daily for six months.
Studien gjordes som en dubbel-blind studie. Pilotstudien visade att ett flertal personer, som behandlades med beredningen enligt föreliggande uppfinning upplevde en klar förbättring vid användandet av den aktuella tand- krämen. Detta resultat förstärks också av att ett flertal av patienter utanför studien som behandlats med tand- krämen rapporterar ett positivt resultat.The study was done as a double-blind study. The pilot study showed that a number of persons treated with the preparation according to the present invention experienced a clear improvement in the use of the toothpaste in question. This result is also reinforced by the fact that a number of patients outside the study who were treated with the toothpaste report a positive result.
Claims (8)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9704789A SE511373C2 (en) | 1997-12-19 | 1997-12-19 | Preparation for the treatment of aphte |
| AU19911/99A AU1991199A (en) | 1997-12-19 | 1998-12-17 | A preparation for the treatment of aphtae |
| PCT/SE1998/002366 WO1999032132A1 (en) | 1997-12-19 | 1998-12-17 | A preparation for the treatment of aphtae |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9704789A SE511373C2 (en) | 1997-12-19 | 1997-12-19 | Preparation for the treatment of aphte |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE9704789D0 SE9704789D0 (en) | 1997-12-19 |
| SE9704789L SE9704789L (en) | 1999-06-20 |
| SE511373C2 true SE511373C2 (en) | 1999-09-20 |
Family
ID=20409495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9704789A SE511373C2 (en) | 1997-12-19 | 1997-12-19 | Preparation for the treatment of aphte |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU1991199A (en) |
| SE (1) | SE511373C2 (en) |
| WO (1) | WO1999032132A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120328537A1 (en) * | 2011-06-23 | 2012-12-27 | Cloonan Richard A | Topical wound management formulation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA82361B (en) * | 1981-02-06 | 1982-12-29 | Biorex Laboratories Ltd | Pharmaceutical composition for treating diseases of the oral cavity |
| US5531982A (en) * | 1987-01-30 | 1996-07-02 | Colgate Palmolive Company | Antimicrobial oral composition |
| US5229425A (en) * | 1990-06-01 | 1993-07-20 | Doyle E. Chastain | Process of producing reference bactericidal endpoint (RBE) limonene |
| JP3345133B2 (en) * | 1992-12-21 | 2002-11-18 | サンスター株式会社 | Toothpaste composition |
-
1997
- 1997-12-19 SE SE9704789A patent/SE511373C2/en unknown
-
1998
- 1998-12-17 AU AU19911/99A patent/AU1991199A/en not_active Abandoned
- 1998-12-17 WO PCT/SE1998/002366 patent/WO1999032132A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| SE9704789D0 (en) | 1997-12-19 |
| AU1991199A (en) | 1999-07-12 |
| WO1999032132A1 (en) | 1999-07-01 |
| SE9704789L (en) | 1999-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1952801B1 (en) | Oral cavity care curative and prophylactic composition | |
| EP1040819B1 (en) | Oral compositions comprising a potassium salt for reducing dental nerve and dentin sensitivity | |
| DE60212673T2 (en) | COMPOSITIONS FOR THE TREATMENT OF XEROSTOMY AND TREATMENT OF RELATED DISEASES | |
| US9107920B2 (en) | Extract of Trigonella foenum-graecum | |
| SE461378B (en) | COMPOSITION FOR MEDICAL TREATMENT AND PREVENTION TO PREVENT PARADONTOPATHY | |
| CZ384898A3 (en) | Antimicrobial preparations for oral hygiene products | |
| US20150335549A1 (en) | Oral Care Composition Containing Ionic Liquids | |
| WO2018151567A1 (en) | Toothpaste composition comprising jade component | |
| Wennström et al. | The effect of mouthririses on parameters characterizing human periodontal disease | |
| CN105997615A (en) | Natural and edible children's mouthwash and preparation method thereof | |
| US5158764A (en) | Dentifrice | |
| CN108042420B (en) | Composition for oral health care and application thereof | |
| CN108245552A (en) | A kind of composition and its application for oral cavity | |
| CN101829027A (en) | Multifunctional mouthwash and preparation method thereof | |
| Southard et al. | Effect of sanguinaria extract on development of plaque and gingivitis when supragingivally delivered as a manual rinse or under pressure in an oral irrigator | |
| CN108158899A (en) | A kind of mouthwash containing vine tea flavone extract and preparation method thereof | |
| CN103599182A (en) | Traditional Chinese medicine composition and preparation method thereof, and oral cavity cleaning and nursing product and preparation method thereof | |
| SE511373C2 (en) | Preparation for the treatment of aphte | |
| WO2017086653A1 (en) | Oral composition and method for preparing same | |
| JPS5855409A (en) | Compositions for preventing and treating periodontal diseases | |
| HU199298B (en) | Compositions comprising several active ingredients for preventing and curing parodontopathy and process for producing the composition | |
| CN108175730B (en) | Composition for oral cavity and application and preparation method thereof | |
| CN114404522B (en) | Chinese herbal medicine composition, gargle and preparation method | |
| JP2005162633A (en) | Salivary secretion promoter and oral composition and food composition containing the same | |
| KR0138248B1 (en) | Oral Hygiene Composition Containing Plant Extracts |